Control of Chemotherapy-Induced Emesis

New England Journal of Medicine

Volumn 329, Issue 24, 1993, Pages 1790-1796

  Wood, Alastair J j ^a   Grunberg, Steven M ^b   Hesketh, Paul J ^c  

^a University of Vermont ^*

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANTINEOPLASTIC AGENT; BENZAMIDE; BENZODIAZEPINE; BUTYROPHENONE; CANNABINOID; CHOLINERGIC RECEPTOR; CORTICOSTEROID; DOPAMINE; DOPAMINE RECEPTOR; DRUG RECEPTOR; HISTAMINE; HISTAMINE RECEPTOR; NEUROTRANSMITTER; OPIATE RECEPTOR; PHENOTHIAZINE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

CANCER; CANCER CHEMOTHERAPY; CHEMORECEPTOR; DIFFERENTIAL DIAGNOSIS; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; NAUSEA; PRIORITY JOURNAL; REVIEW; VOMITING;

ANIMAL; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BRAIN STEM; CHEMORECEPTORS; HUMAN; RECEPTORS, NEUROTRANSMITTER; SUPPORT, NON-U.S. GOV'T; VOMITING;

EID: 0027366610     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199312093292408     Document Type: Review

References (102)

1. Coates A, Abraham S, Kaye SB, On the receiving end -- patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-208
2. Strum SB, McDermed JE, Pileggi J, Riech LP, Whitaker H Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting: a preliminary evaluation. Cancer 1984; 53: 1432-1439
3. Olver IN, Simon RM, Aisner J Antiemetic studies: a methodological discussion. Cancer Treat Rep 1986; 70: 555-563
4. Jordan NS, Schauer PK, Schauer A, The effect of administration rate on cisplatin-induced emesis. J Clin Oncol 1985; 3: 559-561
5. Tonato M, Roila F, Del Favero A Methodology of antiemetic trials: a review. Ann Oncol 1991; 2: 107-114
6. Hesketh PJ, Plagge P, Bryson JC. Single-dose ondansetron for prevention of acute cisplatin-induced emesis: analysis of efficacy and prognostic factors. In: Bianchi AL, Grelot L, Miller AD, King GL, eds. Mechanisms and control of emesis. London: John Libbey, 1992:25-6.
7. Sullivan JR, Leyden MJ, Bell R Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 1983; 309: 796-796
8. D'Acquisto R, Tyson LB, Gralla RJ, The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 1986; 5: 257-257 abstract.
9. Hesketh PJ, Murphy WK, Lester EP, GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 1989; 7: 700-705
10. Borison HL, Wang SC Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5: 193-230
11. Hesketh PJ, Gandara DR Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991; 83: 613-620
12. Carpenter DO Neural mechanisms of emesis. Can J Physiol Pharmacol 1990; 68: 230-236
13. Miller AD, Wilson VJ “Vomiting center” reanalyzed: an electrical stimulation study. Brain Res 1983; 270: 154-158
14. Wang SC. Emetic and antiemetic drugs. In: Root WS, Hofmann FG, eds. Physiological pharmacology: a comprehensive treatise. Vol. II. New York: Academic Press, 1965:255-328.
15. Leslie RA Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus. Neurochem Int 1985; 7: 191-211
16. Andrews PLR, Rapeport WG, Sanger GJ Neuropharmacology of emesis induced by anticancer therapy. Trends Pharmacol Sci 1988; 9: 334-341
17. Andrews PLR, Davis CJ, Bingham S, Davidson HIM, Hawthorn J, Maskell L The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990; 68: 325-345
18. Leslie RA, Shah Y, Thejomayen M, Murphy KM, Robertson HA The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol 1990; 68: 279-288
19. Stafanini E, Clement-Cormier Y Detection of dopamine receptors in the area postrema. Eur J Pharmacol 1981; 74: 257-260
20. Schwartz JC, Agid Y, Bouthenet ML, et al. Neurochemical investigations into the human area postrema. In: Davis CJ, Lake-Bakaar GV, Grahame-Smith DG, eds. Nausea and vomiting: mechanisms and treatment. Berlin, Germany: Springer-Verlag, 1986:18-30.
21. Carpenter DO, Briggs DB, Strominger N Responses of neurons of canine area postrema to neurotransmitters and peptides. Cell Mol Neurobiol 1983; 3: 113-126
22. Carpenter DO, Briggs DB, Strominger N Peptide-induced emesis in dogs. Behav Brain Res 1984; 11: 277-281
23. Sakata Y, Suzuki H, Satoh T, Clinical evaluation of sulpiride against nausea and vomiting during cancer chemotherapy compared with domperidone -- envelope method. Gan To Kagaku Ryoho 1986; 13: 2415-2418
24. Wyant GM A comparative study of eleven anti-emetic drugs in dogs. Can Anaesth Soc J 1962; 9: 399-407
25. Seynaeve C, De Mulder PHM, Verweij J Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear. Pharm Weekbl [Sci] 1991; 13: 1-6
26. 1-receptors in the rat brain: an autoradiographic study. Neuroscience 1981; 6: 15-37
27. Wamsley JK, Lewis MS, Young WS III, Kuhar MJ Autoradiographic localization of muscarinic cholinergic receptors in rat brainstem. J Neurosci 1981; 1: 176-191
28. Sanger GJ New antiemetic drugs. Can J Physiol Pharmacol 1990; 68: 314-324
29. Kobrinsky NL Regulation of nausea and vomiting in cancer chemotherapy: a review with emphasis on opiate mediators. Am J Pediatr Hematol Oncol 1988; 10: 209-213
30. Costello DJ, Borison HL Naloxone antagonizes narcotic self blockade of emesis in the cat. J Pharmacol Exp Ther 1977; 203: 222-230
31. Harris AL, Cantwell BMJ. Mechanisms and treatment of cytotoxic-induced nausea and vomiting. In: Davis CJ, Lake-Bakaar GV, Grahame-Smith DG, eds. Nausea and vomiting: mechanisms and treatment. Berlin, Germany: Springer-Verlag, 1986:78-93.
32. Harris AL Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways. Lancet 1982; 1: 714-716
33. Blancquaert JP, Lefebvre RA, Willems JL Emetic and antiemetic effects of opioids in the dog. Eur J Pharmacol 1986; 128: 143-150
34. Bradley PB, Engel G, Feniuk W, Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986; 25: 563-576
35. Tyers MB 5-HT3 receptors. Ann N Y Acad Sci 1990; 600: 194-202
36. Fozard JR Neuronal 5-HT receptors in the periphery. Neuropharmacology 1984; 23: 1473-1486
37. 3H] GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 1989; 159: 157-164
38. 3H]-BRL 43694, binds to presynaptic sites in the nucleus tractus solitarius of the rat. Br J Pharmacol 1989; 97: Suppl: 414P-414P abstract.
39. Gunning SJ, Hagan RM, Tyers MB Cisplatin induces biochemical and histological changes in the small intestine of the ferret. Br J Pharmacol 1987; 90: 135P-135P abstract.
40. Endo T, Minami M, Monma Y, Saito H, Takeuchi M Emesis-related biochemical and histopathological changes induced by cisplatin in the ferret. J Toxicol Sci 1990; 15: 235-244
41. Cubeddu LX, Hoffman IS, Fuenmayor NT, Finn AL Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810-816
42. Moertel CG, Reitemeier RJ, Gage RP A controlled clinical evaluation of antiemetic drugs. JAMA 1963; 186: 116-118
43. Martin-Jimenez M, Diaz-Rubio E, Sangro B Results of two controlled studies on antiemetic combination against vomiting induced by 5-fluorouracil. Tumori 1987; 73: 499-504
44. Goldstein D, Levi JA, Woods RL, Russell J, Morgan J, Kerestes Z Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy. Oncology 1989; 46: 105-108
45. Gralla RJ, Itri LM, Pisko SE, Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905-909
46. Carr BI, Blayney DW, Goldberg DA, Braly P, Metter GE, Doroshow JH High doses of prochlorperazine for cisplatin-induced emesis: a prospective, random, dose-response study. Cancer 1987; 60: 2165-2169
47. Olver IN, Laidlaw CR, Wolf M, High dose prochlorperazine: prolonged cost effective antiemesis. Proc Am Soc Clin Oncol 1991; 10: 321-321 abstract.
48. Olver IN, Webster LK, Bishop JF, Clarke J, Hillcoat BL A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy. Eur J Cancer Clin Oncol 1989; 25: 1457-1461
49. Saller R, Hellenbrecht D High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis. Eur J Cancer Clin Oncol 1986; 22: 1199-1203
50. Jackson M, Bozzino J, Prasad V, Warenius H Ineffectiveness of droperidol as antiemetic. Drug Intell Clin Pharm 1985; 19: 841-842
51. Grunberg SM, Gala KV, Lampenfeld M, Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol 1984; 2: 782-787
52. Rich WM, Abdulhayoglu G, Di Saia PJ Methylprednisolone as an antiemetic during cancer chemotherapy -- a pilot study. Gynecol Oncol 1980; 9: 193-198
53. Livrea P, Trojano M, Simone IL, Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol 1985; 231: 336-339
54. Chiara S, Campora E, Lionetto R, Bruzzi P, Rosso R Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol 1987; 10: 264-267
55. Roila F, Tonato M, Basurto C, Minotti V, Ballatori E, del Favero A Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. Eur J Cancer Clin Oncol 1987; 23: 615-617
56. Zaglama NE, Rosenblum SL, Sartiano GP, Brady M, Gonzalez MF, Valdivieso JG Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy. Oncology 1986; 43: 27-32
57. Cassileth PA, Lusk EJ, Torri S, Gerson SL Antiemetic efficacy of high-dose dexamethasone in induction therapy in acute nonlymphocytic leukemia. Ann Intern Med 1984; 100: 701-702
58. Aapro MS Present role of corticosteroids as antiemetics. Recent Results Cancer Res 1991; 121: 91-100
59. Sallan SE, Zinberg NE, Frei E III Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293: 795-797
60. Sallan SE, Cronin C, Zellen M, Zinberg NE Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302: 135-138
61. Pomeroy M, Fennelly JJ, Towers M Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 1986; 17: 285-288
62. Niiranen A, Mattson K A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985; 8: 336-340
63. Tyson LB, Gralla RJ, Clark RA, Kris MG, Bordin LA, Bosl GJ Phase I trial of levonantradol in chemotherapy-induced emesis. Am J Clin Oncol 1985; 8: 528-532
64. McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 1988; 6: 243-246
65. Mechoulam R, Breuer A, Feigenbaum JJ, Devane WA Nonpsychotropic synthetic cannabinoids as therapeutic agents. Farmaco 1991; 46: Suppl: 267-276
66. Bowcock SJ, Stockdale AD, Bolton JAR, Kang AA, Retsas S Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy. BMJ 1984; 288: 1879-1879
67. Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone: a double-blind, randomized trial. Cancer 1987; 60: 2816-2822
68. Gralla RJ Metoclopramide: a review of antiemetic trials. Drugs 1983; 25: Suppl 1: 63-73
69. Tortorice PV, O'Connell MB Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 1990; 10: 129-145
70. Kris MG, Tyson LB, Gralla RJ, Clark RA, Allen JC, Reilly LK Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 1983; 309: 433-434
71. Grunberg SM, Ehler E, McDermed JE, Akerley WL Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst 1988; 80: 864-868
72. Fozard JR, Mobarok Ali AT Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 1978; 49: 109-112
73. Kris MG, Gralla RJ, Clark RA, Tyson LB Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol 1988; 6: 659-662
74. Grunberg SM, Stevenson LL, Russell CA, McDermed JE Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989; 7: 1137-1141
75. Addelman M, Erlichman C, Fine S, Warr D, Murray C Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 1990; 8: 337-341
76. Stamatakis L, Michel J, Van Belle S, ICS 205-930: a dose finding study in the prevention of cisplatin induced nausea and vomiting. Proc Am Soc Clin Oncol 1989; 8: 327-327 abstract.
77. Clark RA, Kris MG, Gralla RJ, Tyson LB Serotonin antagonists demonstrate antiemetic effectiveness without extrapyramidal symptoms: analysis of studies with 3 new agents in 155 patients. Proc Am Soc Clin Oncol 1990; 9: 322-322 abstract.
78. Marty M, Pouillart P, Scholl S, Comparison of the 5-hydroxytryptamine (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816-821
79. Bonneterre J, Chevallier B, Metz R, A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990; 8: 1063-1069
80. Beck TM, Ciociola AA, Jones SE, Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy: the Ondansetron Study Group. Ann Intern Med 1993; 118: 407-413
81. Allan SG, Cornbleet MA, Warrington PS, Golland IM, Leonard RCF, Smyth JN Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. BMJ 1984; 289: 878-879
82. Grunberg SM, Akerley WL, Krailo MD, Johnson KB, Baker CR, Cariffe PA Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest 1986; 4: 379-385
83. Roila F, Tonato M, Cognetti F, Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675-678
84. Smyth JF, Coleman RE, Nicolson M, Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ 1991; 303: 1423-1426
85. Van Hazel GA, Frytak S, Anderson SA, O'Fallon JR, Moertel CG, Long HJ A double-blind randomized crossover study comparing high-dose metoclopramide to dexamethasone + prochlorperazine as antiemetics during cisplatin chemotherapy. Proc Am Soc Clin Oncol 1983; 2: 85-85 abstract.
86. Gez E, Ben-Yosef R, Catane R, Brufman G, Biran S Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study. Oncology 1989; 49: 150-154
87. Silvey L, Carpenter JT Jr, Wheeler RH, Lee J, Conolley C A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. J Clin Oncol 1988; 6: 1397-1400
88. Niiranen A, Mattson K Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol 1987; 10: 325-329
89. Cody R, Natale R, Calzone K, Ativan as adjunctive antiemetic and primary anxiolytic therapy in patients receiving cancer chemotherapy. Proc Am Soc Clin Oncol 1991; 10: 340-340 abstract.
90. Kris MG, Gralla RJ, Tyson LB, Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine: results of consecutive trials in 255 patients. Cancer 1985; 55: 527-534
91. Morran C, Smith DC, Anderson DA, McArdle CS Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. BMJ 1979; 1: 1323-1324
92. Sawicka J, Sallan S Transdermal therapeutic system-scopolamine: prevention of vomiting associated with cancer chemotherapy. Proc Am Assoc Cancer Res Am Soc Clin Oncol 1977; 18: 302-302 abstract.
93. Longo DL, Wesley M, Howser D, Hubbard SM, Anderson T, Young RC Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis. Cancer Treat Rep 1982; 66: 1975-1976
94. Meyer BR, O'Mara V, Reidenberg MM A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen. J Clin Oncol 1987; 5: 1994-1997
95. Cunningham D, Forrest GJ, Soukop M, Gilchrist NL, Calder IT, McArdle CS Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs. BMJ 1985; 291: 864-865
96. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695-700
97. Bregni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. Eur J Cancer 1991; 27: 561-565
98. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993; 328: 1076-1080
99. Kris MG, Gralla RJ, Clark RA, Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379-1384
100. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S Controlling delayed vomiting: double-blind randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108-114
101. Morrow GR Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 1982; 68: 585-588
102. Greenberg DB, Surman OS, Clarke J, Baer L Alprazolam for phobic nausea and vomiting related to cancer chemotherapy. Cancer Treat Rep 1987; 71: 549-550